Latest news with #EGFR-mutated
Yahoo
a day ago
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Merck, Daiichi pull approval application for ADC in lung cancer
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co. and Daiichi Sankyo have withdrawn an approval application in the U.S. for a lung cancer drug at the center of a multibillion-dollar alliance the companies formed two years ago. In a short statement Thursday, the companies said they've pulled a Food and Drug Administration submission for an experimental therapy known as patritumab deruxtecan. Merck and Daiichi had been seeking an 'accelerated' approval of the drug in people whose non-small cell lung cancer has a mutation in a gene called EGFR and, last September, reported that it meaningfully delayed tumor progression compared to chemotherapy in a Phase 2 trial. However, Merck and Daiichi have also found that their drug didn't extend survival, the gold standard for a cancer drug. That finding, as well as subsequent discussions with the FDA, led the companies to withdraw their application, according to their statement. The companies will present study results at the American Society of Oncology Meeting on Sunday. This outcome is a 'reminder of how challenging it can be to treat these patients with EGFR-mutated non-small cell lung cancer in the second and later line settings,' said Eliav Barr, the chief medical officer of Merck Research Laboratories, in the statement. Merck currently draws the bulk of its revenue from the cancer immunotherapy Keytruda, which in recent years became the world's top-selling drug. But Keytruda is poised to lose patent protection later this decade, and Merck has been facing increasing skepticism from analysts and investors about its plans to offset those future losses and grow. The company's share price has fallen nearly 40% over the last 12 months. One area of research Merck has looked to is antibody-drug conjugates, a type of targeted cancer medicine seen as a potential way to replace traditional chemotherapies. The company formed a pair of alliances with China-based drugmaker Kelun Biotech in 2022 and, a year later, sprung for a collaboration with Daiichi that could potentially be worth as much as $22 billion. In aligning with Daiichi, Merck may have been spurred on by the success AstraZeneca has had with a similar type of ADC-focused partnership. A 2019 deal between Daiichi and AstraZeneca yielded Enhertu, an ADC that's cleared for use in several cancers and is now a blockbuster medicine. Merck partnered with Daiichi a month after the Japanese company reported Phase 2 data underlying an accelerated approval application for patritumab deruxtecan. But the companies have faced setbacks since. U.S. regulators rejected their ADC last June due to findings at a manufacturing plant. Now, after pulling their application, Merck and Daiichi are searching for a new path forward. The companies are 'conducting further biomarker analyses' to better identify lung cancer patients who might benefit from treatment, said Ken Takeshita, Daiichi's global head of R&D, in the statement. 'We remain confident in the broad development of [our drug],' which includes trials across 15 types of cancer, he added.
Yahoo
3 days ago
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
27-03-2025
- Health
- Yahoo
AstraZeneca says new results reinforce Tagrisso as backbone therapy
New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca's (AZN) TAGRISSO, as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include: LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy; SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO; ORCHARD Phase II platform trial of TAGRISSO plus datopotamab deruxtecan-dlnk in advanced EGFRm NSCLC following disease progression on 1st-line TAGRISSO; FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC. Myung-Ju Ahn, MD, PhD, Professor of Hemato-Oncology at the Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, said: 'A critical goal in treating every patient with lung cancer is to not only extend a patient's life but also maintain quality of life while on treatment. The continued overall survival trend seen here at ELCC in the unresectable Stage III setting and the promising data for combinations that can address progression in the advanced setting, together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment.' Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca, said: 'Having now treated more than one million patients around the world, TAGRISSO has repeatedly transformed expectations for patients with EGFR-mutated lung cancer by not only extending survival but also showing it is possible to maintain quality of life during cancer treatment. The breadth of data at ELCC reinforce TAGRISSO as the backbone therapy for patients with this disease and show that adding savolitinib or datopotamab deruxtecan-dlnk at the time of disease progression can help prolong patients' responses to treatment.' Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on AZN: Disclaimer & DisclosureReport an Issue AstraZeneca call volume above normal and directionally bullish AstraZeneca announces results presented at ELCC on Tagrisso Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal China Woos Foreign CEOs with Call to Resist Protectionism as Trump Weighs Tariffs AstraZeneca (AZN) Invests $2.5B in China R&D Hub
Associated Press
05-03-2025
- Business
- Associated Press
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to decreased cancer cell proliferation and increased apoptosis compared to osimertinib alone. According to the company, this research from Prof. Ruth Keri's laboratory at Cleveland Clinic provides critical independent validation of previous findings from AstraZeneca researchers, confirming that NXP900 can effectively combat resistance mechanisms that limit the effectiveness of EGFR inhibitors like Tagrisso, which generates over $5 billion in annual sales. NXP900, an oral SRC/YES1 kinase inhibitor with a unique mechanism that inhibits both catalytic and scaffolding functions, shows promise in addressing resistance to current standard-of-care treatments. The company is also advancing NXP800, a GCN2 activator in Phase 1b trials for platinum-resistant, ARID1a-mutated ovarian cancer, with encouraging interim data showing partial response and stable disease in several patients. Industry analysts seem to have taken notice of Nuvectis's potential. In February 2025, Lucid Capital Markets reportedly initiated coverage with a BUY rating and an $18 price target, projecting peak sales of over $900 million for NXP900 across multiple cancer indications. This represents significant potential upside potential from current levels. With multiple catalysts expected in 2025, including completion of the NXP900 Phase 1a study, initiation of Phase 1b trials, and updated NXP800 clinical data in Q2, Nuvectis seems to be a fascinating company to watch in 2025. * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Nuvectis Pharma and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Nuvectis Pharma prior to publication. Please review the full disclaimers and compensation disclosures here:. [email protected] Copyright Business Wire 2025. PUB: 03/05/2025 08:44 AM/DISC: 03/05/2025 08:44 AM
